New president for ABPI
pharmafile | February 9, 2015 | News story | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ABPI, Amgen, Pfizer, Whitehead, emms, john kearney
The Association of the British Pharmaceutical Industry has appointed John Kearney as its new president.
Stepping into the role in April, Kearney replaces Jonathan Emms who is moving on following a promotion at Pfizer that sees him relocating to the US.
Kearney is the general manager for UK and Ireland at Amgen and has 35 years of experience in the pharma industry. He held UK and international roles at GlaxoSmithKline and Pfizer before joining Amgen back in 2007.
Being on the board at the ABPI since 2008 he has worked on a number of initiatives, including playing a lead part in its pricing team towards negotiations with the Department of Health to secure the 2014 Pharmaceutical Price Regulation Scheme (PPRS) deal.
ABPI chief executive Stephen Whitehead says: “I am delighted to be working alongside John as president. His unique experience and expertise across the industry will be crucial as he leads the ABPI and the UK pharmaceutical industry through the opportunities and challenges in 2015.”
Kearney adds: “I am delighted to be building on the recent leadership of Jonathan Emms, at a time when the pharmaceutical industry as a whole is delivering such a high quality and quantity of new science and treatment innovations.”
ABPI current president Jonathan Emms who only took over from Deepak Khanna last year, was the UK managing director for Pfizer but has been promoted to global marketing lead, based in New York. He’ll step down from the ABPI following its AGM in April.
Whitehead adds: “It is with sadness that we say goodbye to Jonathan so soon but he leaves with our very best wishes for a fantastic new role and life in America. Jonathan is a passionate and committed leader of the industry and there is no doubt that we are in a better position today thanks to his leadership and collaboration with key health partners.”
Emms says: “It’s been a great privilege to serve as ABPI president and I’m proud of what has been achieved during my tenure. I have every confidence that John will do a great job in leading the ABPI as it continues the work to improve access and uptake of innovative medicines for UK patients, and achieve government’s aspiration of making the UK a leader in life sciences.”
Brett Wells
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
